No abstract available
Keywords:
Cardiac myosin; Ferric carboxymaltose; Sotagliflozin; HFrEF.
MeSH terms
-
Cardiovascular Agents / adverse effects
-
Cardiovascular Agents / therapeutic use*
-
Evidence-Based Medicine
-
Ferric Compounds / therapeutic use
-
Glycosides / therapeutic use
-
Heart Failure, Systolic / diagnosis
-
Heart Failure, Systolic / drug therapy*
-
Heart Failure, Systolic / mortality
-
Heart Failure, Systolic / physiopathology
-
Hospitalization
-
Humans
-
Maltose / analogs & derivatives
-
Maltose / therapeutic use
-
Randomized Controlled Trials as Topic
-
Recovery of Function
-
Research Design
-
Sodium-Glucose Transporter 1 / antagonists & inhibitors
-
Sodium-Glucose Transporter 2 Inhibitors / therapeutic use
-
Stroke Volume / drug effects*
-
Treatment Outcome
-
Urea / analogs & derivatives
-
Urea / therapeutic use
-
Ventricular Function, Left / drug effects*
Substances
-
Cardiovascular Agents
-
Ferric Compounds
-
Glycosides
-
SLC5A1 protein, human
-
Sodium-Glucose Transporter 1
-
Sodium-Glucose Transporter 2 Inhibitors
-
omecamtiv mecarbil
-
ferric carboxymaltose
-
Maltose
-
(2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triol
-
Urea